-
DMG-PEG2000-NH2 Workflow for LNP Design
2026-09-29
DMG-PEG2000-NH2 combines a PEG2000 spacer with a reactive primary amine, making it useful for tunable bioconjugation, liposomal drug delivery, and lipid nanoparticle formulation. This guide connects coupling chemistry with formulation controls, assay design, and practical troubleshooting for reproducible siRNA delivery research.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-28
Hao et al. designed a zirconium-based metal–organic framework nanoparticle that combines glutathione-responsive delivery of the PD-1/PD-L1 blocking peptide AUNP12 with indocyanine green-mediated photothermal therapy. Their findings support a dual-action nanomedicine strategy: near-infrared heating can damage tumor cells while checkpoint blockade and treatment-associated immune activation may help address limitations of photothermal therapy alone.
-
Self-Assembling EVMPs for Extrahepatic mRNA Delivery
2026-09-27
The study introduces self-assembling enveloped virus-mimicking particles (EVMPs) built from engineered peptides and selected phospholipids to address the limited extrahepatic targeting of many mRNA delivery systems. An optimized formulation showed substantial lung-cell transfection and suppressed tumor progression when carrying IL-12 mRNA, while the authors report favorable repeat-dosing and biosafety findings.
-
Mecamylamine Hydrochloride in Gut–Brain Research
2026-09-26
Use mecamylamine as a pharmacological probe to test whether nicotinic receptors contribute to gut–vagus–brain cholinergic signaling—not as proof that a microbial effect is receptor-specific. This practical workflow pairs dose-ranging and matched vehicle controls with the B. fragilis seizure findings, while highlighting the limits of a brain-penetrant, non-selective antagonist.
-
CPI-613 and the Tumor–Immune Metabolic Interface
2026-09-26
CPI-613 research can extend beyond mitochondrial stress and apoptosis to ask how tumor metabolism shapes immune-cell function. This article interprets recent PDHA1 succinylation findings and translates them into practical choices for tumor–macrophage assays.
-
Telmisartan in Ang II Cardiac Hypertrophy Research
2026-09-25
Use Telmisartan as an AT1-receptor control to test whether angiotensin II-driven cardiac remodeling depends on upstream receptor activation. Paired with RIP3/CaMKII measurements, it helps distinguish receptor-level effects from downstream hypertrophy mechanisms without assuming that it directly targets those pathways.
-
Kaempferol Links NF-κB/PTGS2 to Melanocyte Ferroptosis
2026-09-25
A 2026 study reports that kaempferol reduces RSL3-induced ferroptotic injury in primary human melanocytes and identifies NF-κB/PTGS2 signaling as a candidate link between inflammatory activation and oxidative damage. Transcriptomic, pharmacological, cellular, and patient-tissue analyses support the pathway’s relevance, while leaving its precise molecular causality and therapeutic significance for further testing.
-
M344 for Neuroblastoma and Cancer Research
2026-09-24
M344 links HDAC inhibition to practical assays of cancer-cell growth, differentiation, cell-cycle arrest, and apoptosis. This guide translates neuroblastoma findings into a cautious, dose-ranging workflow for cancer models, with troubleshooting advice for solubility and high-dose toxicity.
-
Astrocytic GAT-3 Links GABA to Dentate Gyrus Memory
2026-09-24
A study in the dentate gyrus identifies astrocytic GAT-3 as a route by which GABA can raise astrocyte calcium and enhance excitatory synaptic transmission through presynaptic GluN2B-containing NMDA receptors. The findings connect a glial transport process to contextual fear memory and offer a framework for distinguishing transporter-mediated signaling from receptor-level GABA pharmacology.
-
Substance P Workflows for Pain Research
2026-09-23
Build reproducible Substance P experiments for receptor signaling, pain transmission research, and inflammatory phenotyping. This guide combines peptide-handling discipline with an evidence-informed strategy for controlling spectral and matrix interference.
-
Ribonuclease R for Circular RNA Workflows
2026-09-23
Use Ribonuclease R to deplete linear RNA before circular RNA validation, structure analysis, or sequencing library preparation. This guide pairs RNase R treatment with controls, quantitative starting conditions, and troubleshooting strategies for interpreting resistant RNA without overcalling circularity.
-
Erastin in Drug-Resistant Cancer Models
2026-09-22
Erastin is a ferroptosis inducer with a distinctive role in linking redox vulnerability to chemotherapy resistance. This article explains how its effects on system Xc⁻, oxidative stress, and ABCB1 should shape cancer biology research and combination-assay design.
-
Trifluoperazine 2HCl: Assay Design Guide
2026-09-21
Trifluoperazine 2HCl is a dopamine D2 receptor inhibitor suited to mechanistic studies across neuropharmacology, immunology, and cancer biology. This guide focuses on assay design, orthogonal validation, solution handling, and how to interpret receptor-level data without confusing it with unrelated metabolic targets.
-
Sodium Dicloxacillin Monohydrate: Assay Logic
2026-09-21
Sodium dicloxacillin monohydrate is a research tool for dissecting MSSA inhibition across extracellular and intracellular models. This evidence-led guide connects β-lactam mechanism, pH, exposure, and PK/PD endpoints to better assay decisions.
-
1-myristoylglycerophosphocholine in Cell Assays
2026-09-20
A practical, evidence-based guide to using 1-myristoylglycerophosphocholine (SKU M1340) in viability, proliferation, cytotoxicity, and lipid-signaling experiments. It addresses solvent compatibility, dose selection, controls, data interpretation, and vendor reliability using product specifications and pulmonary-fibrosis literature.